Marcos Langtry

Director of Commercial Development, Allogeneic Cell Therapy • Lonza Ltd

Marcos Langtry is Head of Allogeneic Cell Therapy at Lonza. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions with TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he has acquired extensive experience with aseptically filled, biologic and cell therapy products.

Also speaking

Amro Eid

Jenny Prange

CSO and Co-Founder • Muvon Therapeutics

Stefanos Theoharis

Chief Business Officer • Bone Therapeutics

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.